Intrauterine device

Social media will tell you birth control causes mental health issues, weight gain and infertility – here are the facts

Retrieved on: 
Tuesday, April 9, 2024
Research, Depression, Health, Friends, Faculty, Birth, Infertility, Intrauterine device, Menstrual cycle, Depo, Weight gain, Patient, IUD, Birth control, Social media, Mental health, Fertility, Medroxyprogesterone acetate, Life, Quarterlife, Adolescence, Systematic review, Woman, Progesterone, Family

Some women are reportedly even stopping their birth control as a result of misleading posts they’ve seen on TikTok and Instagram.

Key Points: 
  • Some women are reportedly even stopping their birth control as a result of misleading posts they’ve seen on TikTok and Instagram.
  • These three common misconceptions about birth control are cropping up online and need to be put in context:

1. Contraception causes depression

  • Countless videos on social media discuss the effect hormonal contraceptives have on mental health – with some creators claiming birth control causes mood changes and even depression.
  • Although there’s some correlation between mental health and some forms of contraception, there are many factors at play.
  • The articles in this series explore the questions and bring answers as we navigate this turbulent period of life.
  • The evidence suggests depression is more common in adolescent girls – and diminishes after the first two years of taking these forms of birth control.
  • At present, there’s little conclusive evidence that contraception (both hormonal and non-hormonal types) cause mental health problems.

2. Contraception causes weight gain

  • Another common social media claim is that birth control causes weight gain.
  • There is one form of contraception that is linked to weight gain.
  • The Depo-Provera injection, which is administered every 12 weeks, has been proved to cause weight gain.


This weight gain may be due to the progesterone in the shot, which can cause people to feel hungrier – potentially leading to overeating and weight gain. If you’re concerned about potential weight gain, the injection is not the only form of contraception available. Other forms of hormonal and non-hormonal contraceptives have not been shown to affect your weight.

3. Birth control lowers your fertility

  • Another common claim on social media is that birth control causes fertility issues.
  • Research shows hormonal contraceptives have no affect on fertility.
  • Again, evidence shows that IUDs pose no risk to fertility.
  • A systematic review reports no specific differences in fertility between hormonal and non-hormonal IUDs.


Christopher O'Sullivan does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

3Daughters Announces Three New Appointments to Board of Directors

Retrieved on: 
Wednesday, March 13, 2024
Quotient, Thakeham, Alnylam Pharmaceuticals, CDMO, Birth, Labs, GSK plc, Pharmacy, University, Novartis, Dana–Farber Cancer Institute, IUD, University College London, Embryology, IND, MBA, Woman, Doctor of Philosophy, Intrauterine device, Therapy, Drug development, Allergan, Amersham plc, Takeda Oncology, Chief Justice of Hungary, Pharmacia, Birth control

Miles, Ph.D., and Sarah J. Stevens, Ph.D., to serve on the Company’s Board of Directors.

Key Points: 
  • Miles, Ph.D., and Sarah J. Stevens, Ph.D., to serve on the Company’s Board of Directors.
  • An IND for 3D-001 will be filed this year followed by a Phase 1 clinical trial.
  • Mary Beth Cicero, CEO of 3Daughters, expressed her enthusiasm about the new additions to the board: "We are incredibly excited to have the collective strengths of Michele, Sarah, and Vin on our Board of Directors.
  • With this first product, 3Daughters expects to disrupt the IUD market and establish a position as a major innovator in women's healthcare.

Navigating Birth Control: Expert Advice from Dr. Bana Kashani, OB-GYN

Retrieved on: 
Friday, March 29, 2024
Women, Other Communications, Baby, Maternity, Communications, Practice Management, Family, Health, Consumer, General Health, Birth, Pregnancy, Infertility, Q&A, Intrauterine device, Condom, Menstrual cycle, Sterilization, IUD, Ovulation, Research, Fertility, Pelvic inflammatory disease, Hormonal contraception, Tubing (recreation), STI, Woman, USB On-The-Go, Birth control

In a rapidly evolving landscape of reproductive health, navigating the variety of birth control options can be overwhelming.

Key Points: 
  • In a rapidly evolving landscape of reproductive health, navigating the variety of birth control options can be overwhelming.
  • “When choosing a birth control method, it's essential to consider factors such as efficacy, convenience, side effects, and personal preferences.
  • Dr. Kashani sheds light on various birth control methods in the following Q&A:
    What are the different types of birth control methods available?
  • There is limited evidence to suggest that using birth control methods for an extended period negatively impacts fertility.

Health Advocate Applauds Federal Government in Free Access to Contraceptives for Canadians

Retrieved on: 
Thursday, February 29, 2024
Woman, New Democratic Party, Federation, Government, Pregnancy, Gynaecology, Intrauterine device, Pharmacare, Confidence, Policy, Birth, Reproductive rights, Workforce, Public, Birth control

OTTAWA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The Society of Obstetricians and Gynaecologist of Canada (SOGC) applauds the Canadian government on today’s historic announcement to include free access for prescription contraceptives as part of a National Framework for Pharmacare.

Key Points: 
  • OTTAWA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The Society of Obstetricians and Gynaecologist of Canada (SOGC) applauds the Canadian government on today’s historic announcement to include free access for prescription contraceptives as part of a National Framework for Pharmacare.
  • This announcement begins a generational shift across Canada in terms of access and the future of women’s health care at large.
  • Access to contraception is not only a matter of reproductive rights but also a fundamental aspect of public health and equity.
  • “The SOGC is pleased with today’s announcement from the federal government and its commitment to women’s health care in Canada.

Medicines360 and DKT WomanCare Announce Strategic Partnership to Expand Access to the Hormonal IUD Avibela™

Retrieved on: 
Wednesday, January 31, 2024
SAN, Nausea, Clinical trial, Perforation, Birth, Fibroid, Internal bleeding, Liver failure, Infection, Artery, Pelvic pain, DKT International, Jaundice, Anticoagulant, Blood pressure, Ovarian cyst, Woman, Acne, Organization, Partnership, Endometritis, Angioedema, History, Abscess, Contraindication, DKT, Peritonitis, Rash, Coagulopathy, Dyspareunia, Inflammatory cytokine, Adhesion, Vomiting, Bacterial vaginosis, Headache, Bowel obstruction, IUS, Uterus, STI, Breast cancer, Miscarriage, Patient, Fertility, Sepsis, Marketing, Risk, Stroke, Organ, Streptococcus, Hormone-sensitive cancer, Liver tumor, Cyst, Intrauterine device, GAS, Pregnancy, PID, Social marketing, Vaginitis, Migraine, Myocardial infarction, Health, Brain, Birth control

"As a global nonprofit pharmaceutical organization dedicated to expanding access to affordable reproductive health products for women, DKT WomanCare is an ideal partner for our organization," said Dr. Andrea Olariu, CEO of Medicines360.

Key Points: 
  • "As a global nonprofit pharmaceutical organization dedicated to expanding access to affordable reproductive health products for women, DKT WomanCare is an ideal partner for our organization," said Dr. Andrea Olariu, CEO of Medicines360.
  • “DKT WomanCare looks forward to leveraging our global partnerships and commercial relationships to ensure every woman, regardless of income, can access affordable, high-quality contraception.
  • As the supplier of AVIBELA, Medicines360 will focus on providing quality assurance and regulatory oversight, as well as ensuring sustainable product supply to DKT WomanCare and global procurement agencies.
  • Together, Medicines360 and DKT WomanCare will meet the growing demand for quality-assured, affordable hormonal IUDs and help build a robust and sustainable global contraceptive market.

3Daughters Successfully Closes Over $2 million in First Tranche of Seed Financing Round

Retrieved on: 
Monday, January 22, 2024
Abele, Entrepreneurship, Woman, Reproductive rights, Physics, Argosy Foundation, Intrauterine device, Partnership, Birth, Uterus, IND, IUD, Pain, Copper, Birth control

MANSFIELD, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- 3Daughters , a clinical development company fueling evolutionary healthcare for women, announces closing of the first tranche in excess of $2 million in a Seed Round.

Key Points: 
  • MANSFIELD, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- 3Daughters , a clinical development company fueling evolutionary healthcare for women, announces closing of the first tranche in excess of $2 million in a Seed Round.
  • 3Daughters has a unique and frameless delivery platform, based on physics and geometry, for targeted therapy directly into the uterus.
  • 3D-001, a novel IUD containing copper, a proven spermicide for contraception, is the first product resulting from the technology.
  • This investment marks the next chapter for 3Daughters and allows us to execute our streamlined development plans to move into the clinic.

New fertility research shows that IUDs do not reduce the number of eggs retrieved following ovarian stimulation

Retrieved on: 
Tuesday, October 17, 2023
Woman, Physician, Fertility preservation, Family, Cryopreservation, Reproductive medicine, Comparison, REI, Egg, University, University of Southern California, SGF, Patient, Intrauterine device, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Fertility, Birth control, Copper, Research

Shady Grove Fertility's research team provides reassuring data that patients undergoing egg retrieval can keep IUDs.

Key Points: 
  • Shady Grove Fertility's research team provides reassuring data that patients undergoing egg retrieval can keep IUDs.
  • "Women who are considering fertility preservation are often worried about keeping their IUDs in place throughout the egg retrieval cycle," shares Phillip A. Romanski, M.D., M.Sc.
  • "Our research team was excited to learn that patients can rest assured they can keep their IUDs in place without worrying about the impact of eggs retrieved.
  • This important research can help many women take that next step toward preserving their fertility to help build their future family."

Global Condom Market Outlook & Forecast 2023-2028: Demographics and Demand Insights - Female Condoms on the Rise, APAC Leads the Way - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 23, 2023
Infectious Diseases, General Health, Health, Vagina, Male, Female, Education, Prevalence, STI, HIV, Pharmacy, Taboo, Condom, Vasectomy, Woman, Research, Reckitt, Intrauterine device, STD, Supermarket, Reproduction, Government, Pain, Student, LaTeX, GDP, Bleeding, Risk, LifeStyles Condoms, Vertically transmitted infection, HPV, Growth, Birth control, Retail

Female condoms account for less share of the global condom market, and there is a huge opportunity for growth in the global female condom market.

Key Points: 
  • Female condoms account for less share of the global condom market, and there is a huge opportunity for growth in the global female condom market.
  • APAC held the most substantial global condom market share in 2022, accounting for over 37% in revenue.
  • The high penetration of condoms in countries such as Japan and China helped APAC contribute significantly to both value and volume of the global market.
  • The global condom market is characterized by high demand for male and female condoms.

Want long-term contraception? There are more effective options than the pill. But they can be hard to find

Retrieved on: 
Thursday, June 1, 2023
Workforce, Aura, Migraine, Pregnancy, Senate, Ovary, IUD, Birth, Nursing, Intrauterine device, Uterus, Government, Hormone, Pain, Medicare, Abortion, Swimming, Copper, Hysterectomy, Smoke, Magnetic resonance, Remuneration, GP, PBS, Skin, Breast cancer, Birth control, Hormonal intrauterine device

Australians’ access to a range of contraceptive options depends on where they live and how wealthy they are.

Key Points: 
  • Australians’ access to a range of contraceptive options depends on where they live and how wealthy they are.
  • A recent parliamentary inquiry recommends ways to end this “postcode lottery” for people who want to use long-acting reversible contraception.
  • There are several types of long-acting reversible contraception: the hormonal contraceptive implant, the hormonal intrauterine devices (IUD) and copper IUDs.

How do they work?

    • It releases a progestogen hormone which prevents monthly egg release from the ovary for up to three years.
    • IUDs are small T-shaped devices which are inserted into the uterus.
    • Hormonal IUDs contain a progestogen hormone and mainly work by thickening the cervical mucus and preventing sperm from swimming up into the uterus.

They have additional benefits for some users

    • As well as better protection from pregnancy, some long-acting reversible contraception methods have other benefits.
    • The hormonal IUD, Mirena, for example, reduces heavy menstrual bleeding.
    • This includes people with hormone-driven cancers such as breast cancer, for whom any hormonal contraceptive would be considered unsafe.

Why aren’t they more available?

    • Out-of-pocket IUD insertion-related costs can also vary from zero to hundreds of dollars if people don’t have access to publicly funded services.
    • Here’s what to expect

      On the supply side, too few health professionals provide these essential services.

    • There are multiple successful models of nurse-led long-acting reversible contraception services and postpartum insertion of implants by midwifes nationally and internationally.
    • However, most nurses aren’t able to access Medicare remuneration, which creates additional barriers for this highly skilled workforce to provide these services.

What are the recommendations for reform?

    • The Senate inquiry has recognised these barriers and recommends making contraception universally affordable, and specifically, subsidising copper IUDs.
    • It also recommends adequate remuneration through Medicare for GPs, nurses and midwives to provide long-acting reversible contraception insertion and removal, and collaborative efforts between the government and medical colleges to improve access to workforce training.
    • While the recommendations are welcome, they now need to be turned into actions through adequate funding.

Global Medical Devices Market Report 2023: Sector is Expected to Reach $695.2 Billion by 2031 at a CAGR of 6.2% - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 24, 2023
Medical Devices, Health, Infection, Birth, Medicine, Insulin, Pregnancy, Diabetes, USB On-The-Go, Cardiovascular disease, Ageing, Cancer, Quality of life, Surgical instrument, ECG, Intrauterine device, USD, Hospital, Chronic condition, Patient, Vels Institute of Science, Technology & Advanced Studies, Prevalence, Diagnosis, Condom, FDA, Disease, Medical device

The "Global Medical Devices Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Medical Devices Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.
  • The global medical devices market attained a value of about USD 562.6 billion in 2022.
  • Medical devices have a wide range of applications and can be used in various healthcare settings, including hospitals, clinics, and home care.
  • The medical devices market is driven by the following factors:
    Technological Advancements: Technological advancements in medical devices, such as the development of minimally invasive procedures, advanced materials, and 3D printing, are driving market growth.